Sell4

Hinge Health, Inc.

Total Value

Filing Date

Sep 9, 2026

2 transactions

Trade Summary

On Sep 4, 2026 through Sep 8, 2026, Robinson Elliott, Insider, reported $0 of Hinge Health, Inc. (HNGE) across 2 transactions. The filing covers Class A Common Stock and reflects balanced net activity of $0. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Robinson Elliott
Role: Insider
Location: LARCHMONT, NY

Filing Details

Filing Date: Sep 9, 2026
Transaction Date: Sep 4, 2026
Accession Number: 0001193125-26-386693
Form Type: 4

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Sep 4, 2026	Class A Common Stock	—	—	Sale	—
Sep 8, 2026	Class A Common Stock	—	—	Sale	—

Want live alerts when Robinson Elliott trades again?

Download Insider Trades to track HNGE, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)On September 4, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 7,450 and 6,994 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.17. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.73. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
(F2)On September 8, 2026, BVP X and BVP X Inst sold 21,006 and 19,719 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.58. These shares were sold in multiple transactions at prices ranging from $92.00 to $93.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
(F3)The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson Elliott

(Last)

(First)

(Middle)

C/O BESSEMER VENTURE PARTNERS

1865 PALMER AVENUE, SUITE 104

(Street)

LARCHMONT

10538

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	09/04/2026		S		0⁽¹⁾	D	$0	0	I	See footnote⁽¹⁾⁽³⁾
Class A Common Stock	09/08/2026		S		0⁽²⁾	D	$0	0	I	See footnote⁽²⁾⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On September 4, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 7,450 and 6,994 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.17. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.73. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. On September 8, 2026, BVP X and BVP X Inst sold 21,006 and 19,719 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.58. These shares were sold in multiple transactions at prices ranging from $92.00 to $93.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

	/s/ Augie Wilkinson, Attorney-in-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001193125-26-386693.

Hinge Health, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Want live alerts when Robinson Elliott trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4